NEW DELHI — The country's first indigenously produced vaccine against H1N1 virus will be ready for use from mid-May, The Times of India reported March 4.
The vaccine produced by Ahmedabad-based Zydus Cadila may be rolled out first, followed closely by others from Serum Institute and Panacea Biotec.
The vaccine by indigenous players will most likely be administered as a single dose, and priced for about $5.
While Zydus Cadila is planning a capacity of 10 million to 12 million doses in a year, Panacea and Serum's installed annual capacity is 40 million to 50 million doses.
Zydus Cadila will soon be starting final tests required for launching an injectable vaccine in the market— Phase II/III trials (combined) — a first by any company yet, which will further determine its safety across all age groups.